159 related articles for article (PubMed ID: 10188883)
61. Evaluation of "discordant maturation' in chronic myeloid leukaemia using cultures of primitive progenitor cells and their production of clonogenic progeny (CFU-GM).
Marley SB; Lewis JL; Scott MA; Goldman JM; Gordon MY
Br J Haematol; 1996 Nov; 95(2):299-305. PubMed ID: 8904885
[TBL] [Abstract][Full Text] [Related]
62. Restoration of responsiveness of chronic myeloid leukemia granulocyte-macrophage colony-forming cells to growth regulation in vitro following preincubation with prostaglandin E.
Pelus LM; Gold E; Saletan S; Coleman M
Blood; 1983 Jul; 62(1):158-65. PubMed ID: 6574794
[TBL] [Abstract][Full Text] [Related]
63. Role of TNF alpha in bryostatin-induced inhibition of human hematopoiesis.
Dräger AM; van der Hem KG; Zevenbergen A; Odding JH; Huijgens PC; Schuurhuis GJ
Leukemia; 1999 Jan; 13(1):62-9. PubMed ID: 10049062
[TBL] [Abstract][Full Text] [Related]
64. Defective recloning capacity of granulocyte-macrophage colony-forming cells in chronic myeloid leukaemia.
Olofsson T; Nilsson B
Scand J Haematol; 1986 Feb; 36(2):168-75. PubMed ID: 3458293
[TBL] [Abstract][Full Text] [Related]
65. The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro.
Gebbia V; Citarrella P; Miserendino V; Valenza R; Borsellino N; Pesta A; Pettit R; May S
Tumori; 1992 Jun; 78(3):167-71. PubMed ID: 1440938
[TBL] [Abstract][Full Text] [Related]
66. Mechanism of action of alpha interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors.
Galvani DW; Cawley JC
Br J Haematol; 1989 Dec; 73(4):475-9. PubMed ID: 2611135
[TBL] [Abstract][Full Text] [Related]
67. In vitro toxicity of A 3'-azido-3'-deoxythymidine and hydroxyurea combination on normal myeloid progenitors.
Lerza R; Castello G; Ballarino P; Mela GS; Tredici S; Arboscello E; Mencoboni M; Pannacciulli I
Anticancer Res; 1998; 18(4A):2755-8. PubMed ID: 9703941
[TBL] [Abstract][Full Text] [Related]
68. All-trans retinoic acid combined with interferon-alpha effectively inhibits granulocyte-macrophage colony formation in chronic myeloid leukemia.
Zheng A; Savolainen ER; Koistinen P
Leuk Res; 1996 Mar; 20(3):243-8. PubMed ID: 8637219
[TBL] [Abstract][Full Text] [Related]
69. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
Jayson GC; Crowther D; Prendiville J; McGown AT; Scheid C; Stern P; Young R; Brenchley P; Chang J; Owens S
Br J Cancer; 1995 Aug; 72(2):461-8. PubMed ID: 7640233
[TBL] [Abstract][Full Text] [Related]
70. Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells.
van der Hem KG; Dräger AM; Odding JH; Langenhuijsen MM; Huijgens PC
Leuk Res; 1995 Jan; 19(1):7-13. PubMed ID: 7837820
[TBL] [Abstract][Full Text] [Related]
71. In vivo stimulation of murine haematopoiesis by the antineoplastic agent bryostatin-1.
Gebbia V; Gebbia N; Rausa L; Sharkis SJ; May WS
Pharmacol Res; 1990; 22 Suppl 1():103-4. PubMed ID: 2284223
[No Abstract] [Full Text] [Related]
72. Comparison of the antitumor activity of bryostatins 1, 5, and 8.
Kraft AS; Woodley S; Pettit GR; Gao F; Coll JC; Wagner F
Cancer Chemother Pharmacol; 1996; 37(3):271-8. PubMed ID: 8529289
[TBL] [Abstract][Full Text] [Related]
73. In vivo synergistic effect of the immunomodulator AS101 and the PKC inducer bryostatin.
Kalechman Y; Albeck M; Sredni B
Cell Immunol; 1992 Aug; 143(1):143-53. PubMed ID: 1623562
[TBL] [Abstract][Full Text] [Related]
74. The macrocyclic lactone protein kinase C activator, bryostatin 1, either alone, or in conjunction with recombinant murine granulocyte-macrophage colony-stimulating factor, protects Balb/c and C3H/HeN mice from the lethal in vivo effects of ionizing radiation.
Grant S; Traylor R; Pettit GR; Lin PS
Blood; 1994 Feb; 83(3):663-7. PubMed ID: 8298128
[TBL] [Abstract][Full Text] [Related]
75. Butyric acid: inhibition of non-leukemic and chronic myeloid leukemia granulocyte macrophage clonal growth.
Januszewicz E; Rabizadah E; Novogrodsky A; Shaklai M
Med Oncol Tumor Pharmacother; 1988; 5(4):259-63. PubMed ID: 3193830
[TBL] [Abstract][Full Text] [Related]
76. Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency.
van der Hem KG; Schuurhuis GJ; Dräger AM; Odding JH; Huijgens PC
Leuk Res; 1996 Sep; 20(9):743-50. PubMed ID: 8947584
[TBL] [Abstract][Full Text] [Related]
77. Identification of sibling species of the bryozoan Bugula neritina that produce different anticancer bryostatins and harbor distinct strains of the bacterial symbiont "Candidatus Endobugula sertula".
Davidson SK; Haygood MG
Biol Bull; 1999 Jun; 196(3):273-80. PubMed ID: 10390826
[TBL] [Abstract][Full Text] [Related]
78. Cytokine secretion effected by synergism of the immunomodulator AS101 and the protein kinase C inducer bryostatin.
Sredni B; Kalechman Y; Albeck M; Gross O; Aurbach D; Sharon P; Sehgal SN; Gurwith MJ; Michlin H
Immunology; 1990 Aug; 70(4):473-7. PubMed ID: 2118479
[TBL] [Abstract][Full Text] [Related]
79. A phase I study of intravenous bryostatin 1 in patients with advanced cancer.
Prendiville J; Crowther D; Thatcher N; Woll PJ; Fox BW; McGown A; Testa N; Stern P; McDermott R; Potter M
Br J Cancer; 1993 Aug; 68(2):418-24. PubMed ID: 8347500
[TBL] [Abstract][Full Text] [Related]
80. Regulation of hematopoiesis-IV: The role of interleukin-3 and bryostatin 1 in the growth of erythropoietic progenitors from normal and anemic W/Wv mice.
Leonard JP; May WS; Ihle JN; Pettit GR; Sharkis SJ
Blood; 1988 Nov; 72(5):1492-6. PubMed ID: 3263149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
